Phathom Pharmaceuticals, Inc.

PHAT

NASDAQHealthcareBiotechnology

在 GoAI 中打開

前收盤價

US$8.87

+US$0.27 · +3.14%

8月21日下午4:00 ET

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

56/ 100

GoAI評分

Hold

Wait — insufficient conviction to act

估值

Undervalued

動能

Gaining

情緒

Mixed

風險韌性

Elevated Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Steven L. Basta
上市以來: 2019年10月25日
僱員: 371